Acurx Pharma Granted Korean Patent For DNA Polymerase IIIC Inhibitors Including Compositions‑Of‑Matter, Methods Of Use, And Pharmaceutical Compositions

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has been granted a new patent by the Korean Intellectual Property Office for DNA Polymerase IIIC inhibitors, which includes compositions-of-matter, methods of use, and pharmaceutical compositions. This patent enhances Acurx's intellectual property portfolio, adding to its existing four U.S. patents and patents granted in Israel, Japan, India, Australia, and Korea, all related to its ACX-375C program. Additional patent applications are still under review in other countries.